`a`
Discrete and Continuous Dynamical Systems - Series B (DCDS-B)
 

Modeling prostate cancer response to continuous versus intermittent androgen ablation therapy
Pages: 945 - 967, Issue 4, June 2013

doi:10.3934/dcdsb.2013.18.945      Abstract        References        Full text (759.8K)                  Related Articles

Harsh Vardhan Jain - Department of Mathematics, Florida State University, Tallahassee, FL 32306, United States (email)
Avner Friedman - The Ohio State University, Department of Mathematics, Columbus, OH 43210, United States (email)

1 D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde and H. I. Scher, Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence, J. Natl. Cancer. Inst., 91 (1999), 1869-1876.
2 G. L. Andriole, E. D. Crawford, R. L. Grubb III, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan and C. D. Berg, Mortality results from a randomized prostate-cancer screening trial, N. Engl. J. Med., 360 (2009), 1310-1319.
3 R. R. Berges, J. Vukanovic, J. I. Epstein, M. CarMichel, L. Cisek, D. E. Johnson, R. W. Veltri, P. C. Walsh and J. T. Isaacs, Implication of cell kinetic changes during the progression of human prostatic cancer, Clin. Cancer Res., 1 (1995), 473-480.
4 G. Birkenmeier, F. Struck and R. Gebhardt, Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin, J. Urol., 162 (1999), 897-901.
5 M. L. Cher, G. S. Bova, D. H. Moore, E. J. Small, P. R. Carroll, S. S. Pin, J. I. Epstein, W. B. Isaacs and R. H. Jensen, Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping, Cancer Res., 56 (1996), 3091-3102.
6 M. W. Dunn and M. W. Kazer, Prostate cancer overview, Semin. Oncol. Nurs., 27 (2011), 241-250.
7 S. E. Eikenberry, J. D. Nagy and Y. Kuang, The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model, Biol. Direct, 5 (2010), 24-52.
8 B. J. Feldman and D. Feldman, The development of androgen-independent prostate cancer, Nat. Rev. Cancer, 1 (2001), 34-45.
9 D. Gillatt, Antiandrogen treatments in locally advanced prostate cancer: are they all the same?, J. Cancer Res. Clin. Oncol., 132 (2006), S17-S26.
10 R. F. Gittes, Carcinoma of the prostate, N. Engl. J. Med., 324 (1991), 236-245.
11 M. Gleave, S. L. Goldenberg, N. Bruchovsky and P. Rennie, Intermittent androgen suppression for prostate cancer: Rationale and clinical experience, Prostate Cancer Prostatic Dis., 1 (1998), 289-296.
12 S. L. Goldenberg, N. Bruchovsky, M. E. Gleave, L. D. Sullivan and K. Akakura, Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report, Urology, 45 (1995), 839-844.
13 C. W. Gregory, R. T. Johnson, J. L. Mohler Jr, F. S. French and E. M. Wilson, Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen, Urology, 61 (2001), 2892-2898.
14 M. A. Haider, T. H. van der Kwast, J. Tanguay, A. J. Evans, A. Hashmi, G. Lockwood and J. Trachtenberg, Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer, AJR Am J Roentgenol., 189 (2007), 323-328.
15 C. A. Heinlein and C. Chang, Androgen receptor in prostate cancer, Endocr. Rev., 25 (2004), 276-308.
16 Y. Hirata, N. Bruchovsky and K. Aihara, Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer, J. Theor. Biol., 264 (2010), 517-527.
17 A. M. Ideta, G. Tanaka, T. Takeuchi and K. Aihara, A mathematical model of intermittent androgen suppression for prostate cancer, J. Nonlinear Sci., 18 (2008), 593-614.
18 T. L. Jackson, A mathematical model of prostate tumor growth and androgen-independent relapse, Discrete Cont. Dyn.-B, 4 (2004), 187-201.       
19 T. L. Jackson, A mathematical investigation of the multiple pathways to recurrent prostate cancer: Comparison with experimental data, Neoplasia, 6 (2004), 697-704.
20 H. V. Jain, S. K. Clinton, A. Bhinder and A. Friedman, Mathematical modeling of prostate cancer progression in response to androgen ablation therapy, Proc. Natl. Acad. Sci. U. S. A., 108 (2011), 19701-19706.
21 M. Marcelli, W. D. Tilley, C. M. Wilson, J. E. Griffin, J. D. Wilson and M. J. McPhaul, Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance, Mol. Endocrinol., 4 (1990), 1105-1116.
22 H. C. Monro and E. A Gaffney, Modelling chemotherapy resistance in palliation and failed cure, J. Theor. Biol., 257 (2009), 292-302.
23 W. D. Nes, Y. O. Lukyanenko, Z. H. Jia, S. Quideau, W. N. Howald, T. K. Pratum, R. R. West and J. C. Hutson, Identification of the lipophilic factor produced by macrophages that stimulates steroidogenesis, Endocrinology, 141 (2000), 953-958.
24 T. Portz, Y. Kuang and J. D. Nagy, A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy, AIP Advances, 2 (2012), 011002.
25 L. K. Potter, M. G. Zager and H. A. Barton, Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats, Am. J. Physiol. Endocrinol. Metab., 291 (2006), E952-E964.
26 E. M Wilson and F. S. French, Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate, J. Biol. Chem., 51 (1976), 5620-5629.
27 A. S. Wright, L. N. Thomas, R. C. Douglas, C. B. Lazier and R. S. Rittmaster, Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat, J. Clin. Invest., 98 (1996), 255-263.
28 C. Y-F. Young, B. T. Montgomery, P. E. Andrews, S. Qiu, D. L. Bilhartz and D. J. Tindall, Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP, Cancer Res., 51 (1991), 3748-3752.
29 K. Yörükoglu, S Aktas, C Güler, M. Sade and Z. Kirkali, Volume-weighted mean nuclear volume in renal cell carcinoma, Urology, 52 (1998), 44-47.
30 H. Y. E. Zhau, S. Chang, B. Chen, Y. Wang, H. Zhang, C. Kao, Q. A. Sang, S. J. Pathak and L. W. K. Chung, Androgen-repressed phenotype in human prostate cancer, Proc. Natl. Acad. Sci. U. S. A., 93 (1996), 15152-15157.

Go to top